Columbia Technology Ventures

T cell co-receptor clustering for cancer treatment

This technology is a SLAMF6 bispecific antibody to enhance T-cell activation through compartmentalization that can be used for tumor treatments.

Unmet Need: Safe and targeted T-cell activation for cancer immunotherapy

Current cancer immunotherapies involve inhibition of checkpoint receptors between T cells and tumor cells. These treatments present limitations such as patient unresponsiveness and immune-related adverse events. There is a need to develop highly targeted therapies that reduce the risk of non-specific T-cell activation. Clustering receptors in specific locations on the cell surface is key to enhance T-cell activity.

The Technology: Bispecific co-receptor antibodies for targeted T-cell activation

This technology describes bispecific monoclonal antibodies that target SLAMF6 co-receptors. SLAMF6 is required for T-cell activation, and its location on the cell surface can affect T-cell functions. By promoting or inhibiting SLAMF6 with different TCR complex such as CD3 or CD45, T-cell activation is enhanced. Additionally, antibodies targeting co-receptor functions reduce the risk of activating resting T-cells, minimizing off-target effects.

This technology has been validated with human cells.

Applications:

  • Immunotherapy for cancer treatment
  • Research model for studying co-receptor clustering and T cell activation
  • Targeted T-cell therapeutic intervention
  • Immunomodulation therapy

Advantages:

  • Precise compartmentalization
  • Avoids non-specific T-cell activation
  • Reduced risk of adverse inflammatory immune related effects
  • Compatibility with existing therapies

Lead Inventor:

Adam Mor, M.D. Ph.D.

Patent Information:

Patent Pending

Related Publications:

Tech Ventures Reference: